Funds raised will support ongoing Phase II(b) clinical trial in Basal Cell Carcinoma Nevus Syndrome, an orphan cancer hereditary disease requiring life-long therapy with no approved pharmaceutical treatment License and Manufacturing Partner Mayne Pharma invests $2.8MM PR Newswire TAMPA, Fla. and SAN DIEGO, June 1, 2016 TAMPA, Fla. and SAN DIEGO, June 1, 2016 /PRNewswire/ — HedgePath Pharmaceuticals, Inc. (OTCQB: HPPI), a clinical stage biopharmaceutical company that discovers, develops and plans to commercialize innovative therapeutics for patients with cancer, announcedRead more
- American Rebel (OTCQB: AREB) Sales Grow 79% on Amazon
- GeoVax Comments on Recent Vaccine Development Study Funded by the Gates Foundation
- GrowLife Announces Rights Offering to Shareholders for Investment Opportunity for Marketing, Sales and Technology Expansion
- Mace Brand Announces Free Overnight Shipping of Mace Alert 911 to States Affected by Hurricane Florence
- Amazonas Florestal Ltd. Announced Today That the Company Has Appointed a New CFO and Director, Will be Renewing Its Lumber and Carbon Business in Brazil, and Has Completed Its Business Plan for the Colorado Plantations and Lab
SMALL CAP MARKET NEWS
We release small market news updates daily, 5 times a week! Always check back to get the inside scoop on what going on.
LEVERAGE OUR MASSIVE INVESTOR AUDIENCE!
Stock Investors · Accredited Investors · Hedge Fund InvestorsLearn More